HCA
ACRS icon

Hyperion Capital Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Hyperion Capital Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,861
Closed -$87.9K – 62
2023
Q1 		$87.9K Hold
10,861
– – 0.04% 55
2022
Q4 		$171K Hold
10,861
– – 0.08% 54
2022
Q3 		$171K Hold
10,861
– – 0.08% 55
2022
Q2 		$152K Hold
10,861
– – 0.07% 56
2022
Q1 		$187K Hold
10,861
– – 0.07% 57
2021
Q4 		$158K Buy
+10,861
New +$165K 0.04% 54

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hyperion Capital Advisors's ACRS Position: Q2 2023 in Review

Hyperion Capital Advisors sold out of Aclaris Therapeutics (ACRS) in Q2 2023, closing a stake of 10,861 shares — an estimated $87.9K sold.

Hyperion Capital Advisors first reported a position in ACRS in Q4 2021 and held it in 6 quarters. The position peaked at $187K in Q1 2022. 133 funds tracked by Wall St. Rank hold ACRS as of Q2 2023.

  • Hyperion Capital Advisors reported no remaining Aclaris Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Hyperion Capital Advisors sold 10,861 Aclaris Therapeutics shares in Q2 2023, an estimated $87.9K.
  • Hyperion Capital Advisors first reported a position in Aclaris Therapeutics in Q4 2021 and held it in 6 quarters.
  • Hyperion Capital Advisors's Aclaris Therapeutics position peaked at $187K in Q1 2022.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2023.

Based on Hyperion Capital Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.